286 related articles for article (PubMed ID: 29468916)
1. The safety of gliptins : updated data in 2018.
Scheen AJ
Expert Opin Drug Saf; 2018 Apr; 17(4):387-405. PubMed ID: 29468916
[TBL] [Abstract][Full Text] [Related]
2. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
Scheen AJ
Expert Opin Drug Saf; 2015 Apr; 14(4):505-24. PubMed ID: 25630605
[TBL] [Abstract][Full Text] [Related]
3. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
4. Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.
Lehrke M; Marx N; Patel S; Seck T; Crowe S; Cheng K; von Eynatten M; Johansen OE
Clin Ther; 2014 Aug; 36(8):1130-46. PubMed ID: 25015594
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies.
Scheen AJ
Diabetes Metab; 2018 Nov; 44(5):386-392. PubMed ID: 30126735
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus.
Orime K; Terauchi Y
Expert Opin Pharmacother; 2020 Dec; 21(17):2101-2114. PubMed ID: 32990096
[TBL] [Abstract][Full Text] [Related]
7. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.
Scheen A
Expert Opin Drug Saf; 2013 Jul; 12(4):545-57. PubMed ID: 23621381
[TBL] [Abstract][Full Text] [Related]
8. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Clifton P
Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes.
Stoian AP; Sachinidis A; Stoica RA; Nikolic D; Patti AM; Rizvi AA
Metabolism; 2020 Aug; 109():154295. PubMed ID: 32553739
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
[TBL] [Abstract][Full Text] [Related]
12. Saxagliptin for the treatment of diabetes - a focus on safety.
Cernea S; Cahn A; Raz I
Expert Opin Drug Saf; 2016 May; 15(5):697-707. PubMed ID: 26923222
[TBL] [Abstract][Full Text] [Related]
13. DPP-4 inhibitors: focus on safety.
Tella SH; Rendell MS
Expert Opin Drug Saf; 2015 Jan; 14(1):127-40. PubMed ID: 25488788
[TBL] [Abstract][Full Text] [Related]
14. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Frederich R; Wiviott SD; Hoffman EB; Cavender MA; Udell JA; Desai NR; Mosenzon O; McGuire DK; Ray KK; Leiter LA; Raz I;
N Engl J Med; 2013 Oct; 369(14):1317-26. PubMed ID: 23992601
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.
Rehman MB; Tudrej BV; Soustre J; Buisson M; Archambault P; Pouchain D; Vaillant-Roussel H; Gueyffier F; Faillie JL; Perault-Pochat MC; Cornu C; Boussageon R
Diabetes Metab; 2017 Feb; 43(1):48-58. PubMed ID: 27745828
[TBL] [Abstract][Full Text] [Related]
16. Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis.
Guo WQ; Li L; Su Q; Dai WR; Ye ZL
Value Health; 2017 Dec; 20(10):1427-1430. PubMed ID: 29241903
[TBL] [Abstract][Full Text] [Related]
17. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
[TBL] [Abstract][Full Text] [Related]
18. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
Bonora E; Cigolini M
Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
Kaneko M; Narukawa M
Ann Pharmacother; 2017 Jul; 51(7):570-576. PubMed ID: 28622738
[TBL] [Abstract][Full Text] [Related]
20. A review of gliptins in 2011.
Scheen AJ
Expert Opin Pharmacother; 2012 Jan; 13(1):81-99. PubMed ID: 22149369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
